drugset / Trial / NCT05155995

A Study to Evaluate the Pharmacokinetics and Safety Between HCP2001 and Co-administration of Each Component in Healthy Volunteers

NCT05155995

Phase 1 Completed 71 enrolled Hanmi Pharmaceutical Company Limited
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to evaluate the pharmacokinetic characteristics and safety between HCP2001 and co-administration of each component in fasting and fed conditions respectively in healthy volunteers.

Timeline

Start
2021-09-28
Primary completion
2022-11-27
Completion
2022-11-27

Drugs

EvaluationDrugModalityDoseRoute
Subject HCP2001 Unknown
Subject RLD2007 Unknown
Subject RLD2008 Unknown
Subject RLD2102 Unknown

Indications

No indication recorded.